Ankit Singhal
| Ankit Singhal | |
| Occupation | Entrepreneur, CEO |
|---|---|
| Known for | Co-founder and CEO of Anthrogen |
| Education | Columbia University |
Ankit Singhal is an American entrepreneur and the co-founder and CEO of Anthrogen, an artificial intelligence research laboratory focused on training large-scale protein foundation models for biologics discovery and development. The company was part of Y Combinator's Summer 2024 batch and is based in San Francisco.[1]
Early life and education
Singhal attended Columbia University, where he was a Science Research Fellow and Named Scholar. He studied biophysics and applied mathematics at Columbia College. During his time at Columbia, he worked on non-hemolytic peptide design using generative adversarial networks (GANs), protein thermostability, and chemical assays.[2]
Career
Singhal co-founded Anthrogen alongside Connor Lee, who serves as chief technology officer. The company describes itself as an AI research lab building what it calls "the network behind biological intelligence." Anthrogen's core platform is designed to generate novel proteins and peptides with specified functions, using large foundation models trained on protein sequences and structures. The company's stated goal is to accelerate protein design processes that have traditionally relied on lengthy trial-and-error experimentation.[1]
Anthrogen developed and released Odyssey, which the company describes as a family of protein language models scaled to 102 billion parameters. According to Anthrogen, Odyssey supports multi-objective design goals and introduces novel architectural frameworks for scaling and generalization. The model's API has been made available in early access.[2]
The company's team also includes Steven Strutt, who serves as Head of Platform and previously worked in molecular and cell biology at the Doudna Lab at the University of California, Berkeley, where he focused on protein assay development, high-throughput workflows, functional genomics, and CRISPR-Cas9 research.[2]
In November 2024, Anthrogen was reported to have raised a $4 million seed funding round. The company's stated applications span new therapeutic development, industrial catalysts for sustainable manufacturing, and broader molecular innovation. Anthrogen operates at the intersection of artificial intelligence, deep learning, and biotechnology.[1]
References
- ↑ 1.0 1.1 1.2 "Anthrogen – Y Combinator". 'Y Combinator}'. Retrieved 2026-03-18.
- ↑ 2.0 2.1 2.2 "Anthrogen". 'Anthrogen}'. Retrieved 2026-03-18.